

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10551985
Filing Date	2005-10-04
First Named Inventor	Bamford
Art Unit	1625
Examiner Name	Aulakh
Attorney Docket Number	PB60199USw

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4166853		1979-09-04	McCall	
	2	5789596		1998-08-04	Brieden et al.	
	3	5998518		1999-12-07	Steinmann	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20040082544	A1	2004-04-29	Greco et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	9300313	WO	A2	1993-01-07	Virginia Commonwealth University		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number		10551985	
		Filing Date		2005-10-04	
		First Named Inventor		Bamford	
		Art Unit		1625	
		Examiner Name		Aulakh	
		Attorney Docket Number		PB60199USW	

	2	0206196	WO	A1	2002-01-24	Merck Patent GmbH		<input type="checkbox"/>
	3	03035654	WO	A1	2003-05-01	Ortho-McNeil Pharmaceutical, Inc.		<input type="checkbox"/>
	4	0318029	EP	B1	1989-05-31	Eisai Co., Ltd.		<input type="checkbox"/>
	5	0548798	EP	A1	1993-06-30	Sanwa Kagaku Kenkyusho Co., Ltd.		<input type="checkbox"/>
	6	0607536	EP	B1	1994-07-27	SS Pharmaceutical Co., Ltd.		<input type="checkbox"/>
	7	9500131	WO	A1	1995-01-05	Cambridge Neuroscience, Incorporated		<input type="checkbox"/>
	8	9517385	WO	A1	1995-06-29	Ortho Pharmaceutical Corporation		<input type="checkbox"/>
	9	9312986	WO	A1	1993-07-08	C.R.E.C.A.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	"Crystallization"; Kirk-Othmer Encyclopedia of Chemical Technology; 2002; Vol. 8; pp. 95-147;	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10551985
	Filing Date		2005-10-04
	First Named Inventor		Bamford
	Art Unit		1625
	Examiner Name		Aulakh
	Attorney Docket Number		PB60199USW

2	IZQUIERDO ET AL.; "Rupatadine: A New Selective Histamine H1 Receptor and Platelet-Activating Factor (PAF) Antagonist"; CA 139:301165; 2003;	<input type="checkbox"/>
3	SIMPSON ET AL.; "Fexofenadine: A Review of Its Use in the Management of Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria"; CA 132:231383; 2000;	<input type="checkbox"/>
4	BRAGA ET AL.; "Making Crystals from Crystals: A Green Route to Crystal Engineering and Polymorphism"; Chem. Commun.; 2005; pp. 3635-3645;	<input type="checkbox"/>
5	FLAMAND ET AL.; "Histamine-Induced Inhibition of Leukotriene Biosynthesis in Human Neutrophils: Involvement of the H2 Receptor and cAMP"; Br. J. Pharm.; 2004; Vol. 141; pp. 552-561;	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.